These findings indicate that EPH/Ephrin signalling is associated with ERMS development and aggressiveness, and suggest that EPH/Ephrin targeting might be a promising tool in ERMS treatment, as already suggested for other cancer types. The gene discussed is EPHA1; the disease is cancer.